Summary: Human equilibrative nucleoside transporter 1 (hENT1) transports various nucleoside analogues into cells. Although the single hENT1 promoter region (P1) and the mRNA isoform (a1) have been characterized previously, we have recently identified additional promoter regions P2 and P3 (which primarily generate c1/2/3 mRNAs and d1/2/3/4 mRNAs, respectively) in the human liver. Therefore, this study aimed at identifying the primary hENT1 mRNA isoforms expressed in human hepatocytes, while simultaneously obtaining functional evidence of alternative hENT1 promoter usage. Our results showed that the expressions of hENT1c1, d3, and (to a lesser extent) c2 mRNAs were strikingly predominant over the other mRNA isoforms in human hepatocytes, that the abundant expression of these mRNAs was consistent with the high levels of P2 and P3 promoter activity, and that these promoters were significantly marked by transcriptionally active histone modification in hepatic cells. To summarize, our results demonstrate that, resulting from the manipulated alternative promoter usage, hENT1c1 and d3 (and c2) mRNAs are primarily expressed in human hepatocytes, which suggests that they may play important roles in controlling hENT1 expression levels in those cells. Our findings are expected to provide significant insights into the molecular machinery of hENT1 expression control.
Introduction
Human equilibrative nucleoside transporter 1 (hENT1, SLC29A1) is a representative member of the ENTs that are responsible for cellular facilitative nucleoside transport and is widely expressed throughout the body. 1, 2) The hENT1 protein is localized primarily at the cellular plasma membrane where it can transport a variety of endogenous nucleosides including adenosine and inosine. These nucleosides are ligands for adenosine receptors that possess pleiotropic functions, and it has been shown that hENT1 plays an important role in regulating adenosine receptor activity by facilitating extracellular adenosine uptake. A wellknown example is dipyridamole, which is clinically used as a vasodilator and antithrombotic agent. It has been considered likely that the pharmacological actions induced by dipyridamole are primarily due to its potent inhibitory effect on hENT1-mediated adenosine uptake, which results in an increase in extracellular adenosine availability for the receptors on platelets and vascular endothelial cells. 3) In addition to endogenous nucleosides, a variety of nucleoside analogues are transported into the cells by hENT1, after which they are pharmacologically activated via phosphorylation. 4) Therefore, it has become evident that hENT1 plays important roles in anti-viral and anti-cancer therapies where various nucleoside analogues are prescribed. Recently, we and other researchers have shown that the uptake level of ribavirin, an anti-hepatitis C guanosine analogue, by hENT1 is among the determinant factors that govern its antiviral action in vitro, 5, 6) and that single nucleotide polymorphisms (SNPs) in the SLC29A1 gene (rs6932345 and rs760370) are associated with virological responses in chronic hepatitis C patients. 7, 8) hENT1 also plays a key role in transporting cytotoxic nucleoside analogues into tumor cells. It has been shown that hENT1 functions as a primary gemcitabine uptake transporter, 9) and clinical studies have provided results showing the association of hENT1 protein levels with overall survival and/or diseasefree survival in pancreatic cancer patients who were treated with gemcitabine. 10, 11) Based on the understanding that the hENT1 expression level can significantly affect the pharmacological potency of nucleoside analogues, it is important to understand its expression mechanisms in target cells. While the detailed mechanisms regulating hENT1 expression levels have not yet been fully clarified, the region just upstream from the translational start site has been characterized as its promoter region.
12) Accordingly, the binding sites for several transcription factors (TFs), such as the peroxisome proliferatoractivated receptor ¡ and the hypoxia inducible factor, have been reported within that region. [13] [14] [15] [16] Furthermore, the SNP within the region is also reported to be functional. 17, 18) Based on these reports, this region appears to be dedicated to the regulation of hENT1 expression. Meanwhile, in addition to the above-mentioned region (designated the P1 promoter), we have identified two other promoter regions (P2 and P3) approximately 3.7 and 7.7 kbp (respectively) upstream from the translational start site in the human liver (Fig. 1) . 19) These promoters generate several hENT1 mRNA isoforms containing different 5A-untranslated regions (5A-UTRs) (hENT1a1, b1/2/3/4, c1/2/3, and d1/2/3/4 mRNAs). Although these results suggest that the SLC29A1 gene is equipped with an alternative promoter system for its expression control, the results raise two particularly relevant questions: what functional differences exist among the promoters? and, what mRNA isoforms are predominantly expressed in human liver cells as well as other tissues?
In the present study, we sought to identify the primary hENT1 mRNA isoforms expressed in human hepatocytes, one of the target cells for nucleoside analogues, and to simultaneously obtain evidence for alternative promoter usage of the SLC29A1 gene.
Materials and Methods
Cells and cell culture: Eight human hepatocyte lines (HH187, HH225, HH229, HH268, HH278, HH283, HH291, and HH314) were purchased from Tissue Transformation Technologies (Edison, NJ) or Biopredic international (Rennes, France). The donor characteristics of these lines are shown in Supplemental  Table s1 . Pooled (50-donor) human hepatocytes were obtained from Celsis (Baltimore, MD). The Ethics Committee of the Graduate School of Pharmaceutical Sciences, Chiba University, approved the use of human samples in this study.
Three human hepatoma-derived cells (HepG2 cells, Huh-7 cells, and FLC7 cells) and 293FT cells were used in this study. The HepG2 cells, the Huh-7 cells, and the 293FT cells were obtained from Riken Cell Bank (Tsukuba, Japan), Cell Resource Center for Biomedical Research (Tohoku University, Sendai, Japan), and Life Technologies (Carlsbad, CA), respectively. The FLC7 cells were provided by Dr. Seishi Nagamori (Kyorin University, Tokyo, Japan). The HepG2 cells, the Huh-7 cells, and the FLC-7 cells were respectively cultured in Dulbecco's modified Eagle's medium (D-MEM) (Life Technologies), RPMI1640 medium (Life Technologies), and D-MEM/F-12 (Life Technologies). The 293FT cells were grown in D-MEM supplemented with Minimum Essential Medium Non-Essential Amino Acids (Life Technologies), GlutaMAX (Life Technologies), and G418 disulfate salt (500 µg/mL, Sigma-Aldrich, St. Louis, MO). Each medium was supplemented with 10% (v/v) fetal bovine serum, penicillin and streptomycin, and all cells were maintained at 37°C with 5% CO 2 .
cDNA cloning and in vitro transcription: hENT1a1, hENT1c1, and hENT1d3 cDNA were obtained from human liver cDNA 19) by polymerase chain reaction (PCR) with specific primers (Supplemental Table s2 ). Each hENT1 cDNA product was separately cloned into pcDNA3.1(¹)Neo vector (Life Technologies). The DNA sequence of each insert was confirmed by a method described previously. 19) hENT1a1, hENT1c1, and hENT1d3 mRNA were produced from the above-prepared plasmids using an in vitro transcription T7 kit (Takara Bio, Shiga, Japan). Template plasmids were eliminated by DNase I digestion.
Total RNA isolation and cDNA synthesis: Total RNA isolation from hepatic cells was performed using a Nucleospin RNA II kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany) according to the manufacturer's protocol, and the genomic DNA was eliminated via DNase I digestion. cDNA synthesis from the extracted RNA (1 µg) was performed using a High Capacity cDNA Reverse Transcription kit with random hexamers (Life Technologies), as described previously. 19) cDNAs for the standard curves were also synthesized from each hENT1 mRNA isoform at different copy numbers [1, 5, 25, 50 , 100, 250 copies (©10 The expression levels of the hENT1 mRNA isoforms in human hepatic cells were analyzed by a SYBR green-based qPCR method using specific primers for total hENT1 mRNA, as well as hENT1a1 mRNA, all hENT1b mRNA isoforms, all hENT1c mRNA isoforms, and all hENT1d mRNA isoforms (hereafter referred to as hENT1b, hENT1c, and hENT1d, respectively). The expression levels of hENT1 mRNA isoforms were normalized using the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression level. In addition, hENT1a1, hENT1c, and hENT1d mRNA copy numbers (copies/µg total RNA) were determined using the standard curves.
RNA ligase-mediated 5¤-rapid amplification of cDNA ends (RLM-5¤-RACE) and reverse-transcriptase PCR (RT-PCR): RLM-5A-RACE was performed using a GeneRacer RLM-RACE Kit (Life Technologies) according to the manufacturer's protocol. cDNA for RLM-5A-RACE was prepared from HH187 and HepG2 cells. The first RT-PCR was performed using specific primers for hENT1c, hENT1d, or the adaptor. Subsequently, the nested PCR was performed using different primer sets, after which the products were subjected to DNA sequence analysis.
RT-PCR for detection of hENT1c and d mRNA isoform expression was performed using primer sets that were designed to span an exon ¡.
Short-hairpin RNA (shRNA)-mediated knockdown of hENT1d mRNA: In order to archive an isoform-specific mRNA knockdown, it is necessary to design an RNAi target sequence within the 5A-UTR region of each mRNA isoform. Based on this requirement, an hENT1d mRNA-specific shRNA sequence was identified using the Target Sequence Selector (Clontech, Mountain View, CA). Because we were unable to design an hENT1c mRNAspecific shRNA (see the supplemental material), only the hENT1d mRNA could be applied to the isoform-specific knockdown experiment.
The shRNA target sequence for hENT1d mRNA knockdown (dKD-shRNA, Supplemental Table s2 and Fig. 1 ) and the scramble shRNA sequence (control-shRNA, Supplemental Table s2 ) were independently inserted into the RNAi-Ready pSIREN-RetroQ Vector (Clontech). The retrovirus carrying dKD-shRNA or controlshRNA was then separately transduced into HepG2 cells to develop the shRNA-expressing cells (dKD-HepG2 cells or controlHepG2 cells).
Transient transfection and luciferase reporter gene assay: Transient transfection and luciferase reporter gene assays were performed primarily via previously described methods. 19) Preparation of pGL4.17 firefly luciferase reporter plasmids (Promega, Madison, WI) containing the P1 promoter region (¹1883/+143), the P2 promoter region (¹2000/+29, previously referred to as P2.1), or the P3 promoter region (¹1945/+141) was described in a previous study. 19) pGL4.70 Renilla luciferase reporter plasmids (Promega) were used as an internal control.
Chromatin immunoprecipitation (ChIP) assay: Chromatin immunoprecipitation assays were performed in HepG2 cells and FLC7 cells using a ChIP-IT kit (Active Motif, Carlsbad, CA) according to the manufacturer's protocol. Sheared chromatin was prepared from cross-linked cells using a sonicator. Magna ChIP protein G magnetic beads (Millipore, Bedford, MA), anti-histone H3 acetylated lysine 9 (H3K9ac) antibodies (Millipore), antihistone H3 antibodies (Abcam, Cambridge, UK) and normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were used. "Input DNA" refers to the sample prepared from chromatin using the same treatments, except for immunoprecipitation.
A SYBR green-based qPCR method was used for quantification of precipitated DNA amounts of the P1 and P2 promoters or the 3A-intergenic region (2,723 bp downstream from translation stop codon). A fluorescence probe-based qPCR was used for detection of the P3 promoter region. Values were represented as fold enrichment, and then the values of H3K9ac were normalized for the value obtained from the unmodified histone H3 antibodies (H3K9ac/H3). Sequence analysis and others: The normalized CpG dinucleotide (CpG) content in the promoter region (¹500/+500, where +1 indicated the position of the most upstream transcription start site in the region) was calculated. 20, 21) When searching the upstream open reading frame (uORF) in 5A-UTR, the Kozak sequence 22) was taken into consideration. The primer sequences and their positions are shown in Supplemental Table s2 and Figure 1 , respectively. Detailed information about the above procedures is provided in the Supplemental materials.
Results
Expression profile of hENT1 mRNA isoforms in human hepatocytes and hepatoma cells: When examining the expression profile of hENT1 mRNA isoforms in the pooled (50-donor) human hepatocytes, HepG2 cells, Huh-7 cells, and FLC7 cells, qPCR was performed using the GAPDH mRNA as an internal control ( Fig. 2A) . Pooled hepatocytes were used based on the expectation that the individual variability of mRNA expression levels would be masked. The results showed that hENT1c and hENT1d mRNA isoforms were abundantly expressed in all the cells examined, while the hENT1a1 mRNA expression level was significantly lower, and the hENT1b mRNA isoform expression was only detected at trace levels. To confirm mRNA expression level difference, the copy numbers of hENT1a1, c, and d mRNA isoforms in pooled human hepatocytes and hepatoma cells were determined using an absolute qPCR method. Consistent with the results described above, the hENT1c and hENT1d mRNA copies in human hepatic cells were 62-172-fold, and 64-93-fold larger than that of hENT1a1 mRNA, respectively ( Table 1) .
To enhance verification of the predominant expression of hENT1d mRNA in hepatic cells, an mRNA knockdown experiment was performed using the hENT1d mRNA-specific shRNA in HepG2 cells. This experiment was, unfortunately, not applicable to hENT1c mRNA, as described in Materials and Methods. As can be seen in Figure 2B , the results showed that the hENT1d shRNA, but not the scramble shRNA, reduced the hENT1d mRNA level to 25 « 3 (%) without significant effects on the hENT1c mRNA levels in HepG2 cells. Consequently, the total hENT1 mRNA level in dKD-HepG2 cells was 52 « 19 (%) of that of the control-HepG2 cells, indicating that the hENT1d mRNA amount apparently accounted for approximately half of the total hENT1 mRNA amount.
To determine how hENT1c and hENT1d mRNA expression levels varied among hepatocyte lines and to determine if significant expressions of hENT1a1 or 1b mRNA isoforms could be observed in a single donor, qPCR was performed using cDNA obtained from seven human hepatocytes lines. As with the case of pooled human hepatocytes, hENT1c and hENT1d mRNA expressions were highly abundant (Fig. 2C) , and no significant hENT1a1 or hENT1b mRNA expressions were detected (data not shown). However, differences were found in the ratio between hENT1c and hENT1d mRNA levels between individual lines and the hENT1d mRNA levels were more variable [1.21 « 0.85 (©10 2 ), with a 9.2-fold maximum difference] than hENT1c mRNA levels [1.09 « 0.39 (©10 2 ), with a 3.1-fold maximum difference]. These results clearly showed that hENT1c and hENT1d mRNA isoforms were primarily expressed in human hepatocytes as well as human hepatoma cells.
Differential transactivation property of hENT1 alternative promoters in human hepatic cells: To understand the mechanisms underlying differential expression levels among hENT1 mRNA isoforms, the transactivation properties of alternative promoters (P1, P2, and P3, which are responsible for a1, c, and d mRNA transcription, respectively) were examined in hepatoma cells (Fig. 3A) . We showed that the P2 and P3 promoters were more active than the P1 promoter in HepG2 cells, which is consistent with our previous results. 19) In addition, the P2 and P3 promoters were found to be strongly activated in both Huh-7 cells and FLC-7 cells, while the P1 promoter was inert in these cells. These results showed that the P2 and P3 promoters exerted transactivation ability in human hepatic cells, while the P1 promoter did not.
The above results prompted us to investigate whether different sequence characteristics could be found among the promoter regions. DNA sequence analysis results showed that the vicinity of the transcription start site in the P2 and P3 promoters was enriched with CpG, and that the normalized CpG contents were 0.83 and 0.57, respectively (Fig. 3B) . In contrast, the P1 promoter lacked CpG despite the fact that the GC content (61%) was not significantly different from those of the P2 and P3 promoters (70% and 64%, respectively). Another difference was that a TATA-box motif (ATAAAAATA, ¹40/¹32) was predicted in the P1 promoter, but not in the P2 or P3 promoters. Collectively, the sequence analyses clarified that the P2 and P3 promoters were CpG-rich TATA-less promoters, and that the P1 promoter was a CpG-depleted TATAcontaining promoter.
Histone H3 lysine 9 acetylation status in the promoter region: To obtain further evidence that P2 and P3 promoters are activated in hepatic cells, the extent of histone H3 lysine 9 acetylation (H3K9ac), which is one of the well-known markers associated with active transcription in genomic promoter regions, 23, 24) was examined by ChIP assays (Fig. 4) . The results showed that H3K9ac was more enriched in the P2 and P3 promoters than in the 3A-intergenic region, while enrichment amounts between the P1 promoter and the 3A-intergenic region in HepG2 cells were comparable. Similar results were also obtained using FLC7 cells. These results showed that the genomic region of the P2 and P3 promoters was in a transcriptionally active state in HepG2 cells and FLC7 cells, which was consistent with the results of Fig. 2 . Expression profile of hENT1 mRNA isoforms in human hepatocyte and hepatoma cells A: qPCR was performed to characterize the hENT1 mRNA isoform expression profile in pooled (50-donor) human hepatocytes and hepatoma cells (HepG2 cells, Huh-7 cells, and FLC7 cells) using specific primer sets for hENT1a1, b, c, and d mRNA. The hENT1 mRNA level was normalized using the GAPDH mRNA level. The asterisks indicate that hENT1b mRNA expression was detectable, but that the levels were too low to be shown in the same figure as the others. Experiments were performed in duplicate, and each value is the mean « S.D. obtained from three separate assays. B: hENT1d mRNA isoform-specific knockdown was performed using the shRNA that targeted to the 5A-UTR of hENT1d mRNA (dKD-shRNA). HepG2 cells that stably expressed dKD-shRNA (dKD-HepG2 cells), and HepG2 cells stably expressing the scramble shRNA (control-HepG2 cells) were prepared using a retroviral expression system. The expression levels of the total hENT1 mRNA, hENT1c mRNA, and hENT1d mRNA were independently determined by real-time PCR. The results are presented as percentages of the relative expression levels of that of each mRNA in the control-HepG2 cells, which was set at 100%. Each value is the mean « S.D. of the values obtained from three separate HepG2 cell preparations. C: qPCR was performed to examine hENT1c and hENT1d mRNA expression variability among individual human hepatocyte lines. The hENT1c mRNA levels are plotted on the x-axis, while the hENT1d mRNA levels are plotted on the y-axis. The hENT1 mRNA level was normalized using the GAPDH mRNA level. Experiments were performed in duplicate, and each value is the mean « S.D. from three separate assays. promoter activity analyses.
Identification of primary hENT1 mRNA isoforms in human hepatocytes and hepatoma cells: hENT1c and d mRNA groups consist of three (c1, c2, and c3) and four (d1, d2, d3, and d4) mRNA isoforms ( Fig. 1) , respectively, and our qPCR methods were unable to discriminate among their mRNA expressions. To determine if the predominant hENT1d mRNA isoforms are either d1/2 or d3/4, 5A-RACE PCR was performed using HH187 and HepG2 cells. In the results, it was found that the band indicative of hENT1d3/4 mRNA expression was predominantly amplified over the longer one, which contained a previously unidentified transcription start site (asterisk), and the band indicative of hENT1d1/2 mRNA expression was barely detectable (Fig. 5A) , thus showing that the hENT1d3/4 mRNA levels were much higher than the others. We also confirmed that hENT1c mRNAs are exclusively generated from the previously identified transcription start site (Fig. 5A) .
Next, RT-PCR analysis was performed to distinguish among c1, c2, and c3 mRNA isoforms and between the d3 and d4 mRNA isoforms. The results showed that the hENT1c1 and (to a lesser extent) c2 mRNA isoforms were expressed in all hepatic cells examined (Fig. 5B) , while hENT1c3 mRNA expression was not observed. As for the hENT1d mRNAs, the hENT1d3 mRNA levels were apparently predominant over d4 mRNA levels. Therefore, the results showed that hENT1c1 and d3 were the primary mRNA isoforms in human hepatocytes, and that hENT1c2 mRNA also contributed somewhat to total hENT1 mRNA expression.
hENT1c1, c2, and d3 mRNAs have distinct 5A-UTRs, as shown in Figures 1 and 5C , which may provide targets for translational regulation. 25) To obtain insights into those regulatory mechanisms, sequence analysis was performed. The results identified two uORFs (with amino acid lengths of 6 and 46) in the 5A-UTR of d3 mRNA, while none could be found in the 5A-UTRs of c1 or c2. No in-frame ATG embedded in the Kozak sequence was identified in any of the 5A-UTRs. Another element that is potentially involved with translation regulation is the secondary structures of the 5A-UTRs. The results of in silico prediction showed that all three 5A-UTRs including exons 1 and 2, appeared to have their own structural properties, and that the extent of their complexity was predicted to be c2 (99 kcal/mol) > d3 (75 kcal/mol) > c1 (65 kcal/mol) (Supplemental Fig. s1 ).
Discussion
Our results clearly demonstrate that, among the hENT1 mRNA isoforms, hENT1c1, d3 and (to a lesser extent) c2 mRNAs are predominantly expressed in human hepatocytes and hepatoma cells. Therefore, it is considered likely that these mRNA isoforms play important roles in controlling the hENT1 expression levels in human hepatocytes. This is relevant to our previous results showing that the differential hENT1d mRNA expression levels in HH268, HH283, and HH291 (also confirmed in this study) are associated with their different hENT1 transport activities. 19) However, we should disclose that, despite the lowered total hENT1 mRNA level, the dKD-HepG2 cells showed levels of ENT1 activity (NBMPR-sensitive adenosine uptake) that were comparable with the control-HepG2 cells (data not shown). This observation suggests that the hENT1c and d mRNA levels may not always translate directly into functional levels due to as yet unidentified compensatory post-transcriptional regulation mechanisms. Considering the complex structure of the hENT1 gene, along with its physiological roles in cellular nucleotide homeostasis, it can be assumed that both cases may be true depending on the cellular circumstances. Identification of the precise functions of each promoter and mRNA isoform in control of the hENT1 functional level will definitely need to await further studies, but several Fig. 3 . Characterization of the SLC29A1 gene alternative promoter regions A: The transactivation properties of the P1, P2 and P3 promoter regions were examined by luciferase assays. The firefly luciferase plasmids containing one of the promoters were transfected into HepG2 cells, Huh-7 cells, or FLC7 cells. The Renilla luciferase plasmids were used as transfection control and promoter-less plasmids (empty) were used as background control. The transcriptional activity of each promoter was determined by calculating the relative ratio of luciferase activity levels (firefly/Renilla) as the ratio obtained from empty plasmids was set to 1. Experiments were performed in duplicate, and each value is the mean « S.D. from three separate assays. B: CpG sequence analyses were conducted focusing on the region +1500/¹500 as the transcription start site located at the most 5A-side was set to +1. The shadowed regions indicate exons, and vertical lines indicate positions of CpG sequence. Detailed sequence analyses were performed while narrowing down the region to +500/¹500 (dashed lines). The GC content was counted and normalized CpG was calculated using the formula shown in Materials and Methods.
possibilities are given in this discussion.
The findings obtained from our present study provide clear evidence for manipulated utilization of the alternative promoters in the hENT1 gene. This may not be surprising when the data from genome-wide analysis claiming that 30-60% of the human genes have multiple alternative promoters is taken into consideration. 26, 27) One possible mechanism behind the strong activation of the P2 and P3 promoters in hepatocytes is the involvement of hepatocyteenriched TFs. However, no binding elements of such hepatocyteenriched factors have been identified in their promoters (unpublished observation), and hENT1c and d mRNA levels are approximately comparable between HepG2 cells and FLC7 cells, despite the fact that the hepatocyte nuclear factor 4¡ is expressed differentially in these cells. 28) Therefore, another possibility, involvement of a ubiquitously activated system, could more plausibly explain the strong P2 and P3 promoter activations. We found that these promoters show a high rate of CpG occurrence (normalized CpG scores > 0.5), and that they are marked by H3K9 acetylation, which is a recognized hallmark of transcriptionally activated CpG promoters. 23, 24) Currently, it has become widely accepted that a promoter possessing normalized CpG > 0.5 is to be regarded as a high CpG promoter (HCP), and that HCPs are overrepresented in ubiquitously expressed genes. 21, 29, 30) Consistent with this notion, we have observed abundant expression of hENT1c and d mRNAs in human lung, pancreas, intestine, and kidney-derived cells (unpublished observation). Based on these findings, it is very likely that the P2 and P3 promoters are activated in not only hepatocytes, but in various other cells, thus resulting in the ubiquitous expression profile of hENT1c and d mRNAs. It may also be worthwhile to mention that CpG promoters are often accompanied by broad transcription initiation sites, 31) which may draw further attention to the possibility that low levels of hENT1b and d1/2 mRNA isoforms result from leaky transcription from the P2 and P3 promoters, respectively.
On the other hand, we found that hENT1a1 and b mRNAs played only a minimal and negligible role in hENT1 expression in human hepatocytes. hENT1b mRNA aside, the significantly low hENT1a1 mRNA expression level in human hepatocytes is somewhat surprising since several reports have focused on the P1 promoter when identifying regulatory elements and the functional SNP (rs747199). The results of these reports accentuate that the P1 is a bona fide promoter, but it should also be noted that the cells examined in these studies are not hepatocytes.
The critical differences of the P1 promoter, in comparison with the P2 and P3 promoters, are focused on the presence of a TATAbox and the remarkably low CpGs number, despite the fact that all three promoters have comparable GC content levels. Considering the report showing that CpG-less, TATA-box-containing promoters are prevalent amongst tissue-specific genes, 21, 31) it is possible that hepatocytes are not the target cells of the P1 promoter. In addition, it is possible that the P1 is an inducible-type promoter, based on the report showing that CpG-less promoters are overrepresented in the gene responses to biotic or external stimulus. 30) While it is currently unclear how the P1 promoter is regulated, we assume that specific mechanisms preventing its activation exist in human hepatocytes.
In the genes generating alternatively transcribed mRNA isoforms that share the identical protein coding regions, such as RUNX1, OTX2 and SHOX genes, it is believed that the individual mRNAs have distinctive roles related to controlling eventual protein mass in a tissue-, development-, or signal-dependent manner. 26) Furthermore, it is believed that those roles are not solely played by promoters, but that the 5A-UTRs of the mRNA are also involved. 32) Therefore, it is possible that hENT1c1 (c2) and hENT1d3 mRNAs provide an isoform-dependent regulatory mechanism in which the corresponding promoter and 5A-UTR are utilized in an orchestrated manner.
One clue implying their functional difference can be found in Figure 2C , in which the hENT1d mRNA level shows higher variability than that of hENT1c mRNA. Although it is premature to state so categorically, the differences in CpG contents between the P2 and P3 promoters (0.83 vs. 0.57) might be related to such differential behaviors, because the results of recent reports show that CpG content and CpG island length are likely to define the regulatory properties of the promoter by determining nucleosome density. 33) On the other hand, it should be noted that the two uORFs are exclusively found in the 5A-UTR of hENT1d3 mRNA. Because it is well known that uORFs often have repressive effects on protein translation, 34) the two uORFs may play a similar repressive role in translation efficacy under certain conditions. Moreover, it may also be worthwhile to mention that the secondary 5A-UTR structure of d3 mRNA is expected to be more complicated than that of c1 mRNA, because it has been suggested that the higher degree of secondary structure somehow decreases translation efficiency. 25) Taken together, although we understand it may be a speculative statement, it is possible that hENT1d3 mRNA provides a crucial target for flexible control of the total hENT1 mRNA level, while hENT1c1 mRNA ensures its basic level, at least in human hepatocytes. In future studies, it would be an intriguing issue to clarify the distinctive roles played by each hENT1 mRNA isoform, and how they coordinate their efforts to control the hENT1 protein level in human hepatocytes, as well as other cell types.
In conclusion, our results show that hENT1c1, d3, and (to a lesser extent) c2, but not a1, are the primary mRNA isoforms in human hepatocytes, that the P2 and P3 promoter activities are apparently regulated in an independent manner, and that the 5A-UTRs of three hENT1 mRNAs might provide differential impacts on the post-transcriptional regulation of gene expression, which highlights the existence of alternative promoter-driven complex mechanisms underlying hENT1 expression in human hepatocytes. In addition, it should be emphasized that such alternative promoter usage is likely to occur in other cell types as well. Therefore, our present findings establish basic information that is applicable to the clarification of tissue-specific regulatory mechanisms for hENT1 expression in various cells including hepatocytes. Furthermore, it is possible that the SNPs found in the non-coding region may affect promoter activity, mRNA stability, and/or translational efficiency in a promoter/mRNA isoform-specific and tissue-dependent manner. Therefore, it is important to determine what mRNA isoforms are primarily expressed in the cells of interest, and a step-by-step clarification of the transcriptional-and post-transcriptional mechanisms will be necessary for fully understanding how hENT1 expression level is determined in the cells. We hope that such clarifications ultimately contribute to providing useful information for improvements in the efficacy of nucleoside analogue-based therapy.
